$NOVO B (+0,28 %) Stock analysis now available on YT: https://youtu.be/u8gyvfZYGRg?si=b_cAP1XTmSpUFtd2

https://www.n-tv.de/panorama/Mehrere-Abnehmspritzen-Patienten-erleiden-schwere-Sehschaeden-id30053721.html

This can be $NOVO B (+0,28 %) very unpleasant and also expensive.

I realized that my portfolio is very tech-heavy and has been underperforming the market the last few days. I thought I would ask several AIs (for fun) how they would adjust my portfolio to remain growth-oriented but with more diversification and some stability.

Here is the list:

Tech:

6% $NV

5% $GOOGL (+4,38 %)

5% $AMZN (+2 %)

4% $MSFT (-0,83 %)

5% $ASML (-1,4 %)

5% $2330

4% $CSU (+2,14 %)

5% $PANW (-1,02 %) (new)

4% $CRWD (-1,41 %)

6% $INTU (+1,23 %) (new)

4% $CRM

Industry:

3% $ETN (+1,15 %) (new)

3% $APH (+1,41 %)

3% $HEI (+0,17 %)

Health:

4% $NOVO B (+0,28 %)

4% $LLY (+2 %) (new)

3% $ISRG (+1,54 %) (new)

Finances:

4% $V (+1,36 %)

3% $NU (+3,39 %)

Energy/commodities:

6% $LIN (+1,1 %) (new)

2% $NEE (-0,87 %) (new)

Infrastructure:

3% $WM (new)

Consumption:

9% $COST (+0,95 %) (new)

The Ki:

BYD, Xiaomi, Iris Energy, Hims and Hers, Sofi, Applied Digital, Coreweave, Ondas, Rocket lab. Quasi China and all the hype stocks

However, AI has been arguing with itself. It thought Crowdstrike should be replaced by Palo Alto and, if Palo Alto was in, it should be replaced by Crowdstrike. The same with Novo and Eli lilly, visa and mastercard, salesforce and service now.

What do you think of the AI "optimized portfolio"?

Good evening, Grüezi mitenand & Glück auf !

I've had my securities account with Swissquote for about 3 months now & I'd be interested to hear what you have to say.

First of all: I simply sold everything at TR in Germany & then made a fresh start here in Switzerland.

I started with 10x $VWRL (+1,2 %) as a foundation stone. Since then, I've been adding CHF 300 per month - but the plan is to increase this savings plan to at least CHF 500 per month at first & later to CHF 800 & CHF 1000. Then I looked at what else I would like to have in my portfolio (again).

The results are as follows:

8 x $AD Ahold Delhaize

6 x $BATS British American Tobacco

1 x $CRM Salesforce

10 x $EQNR Equinor

10 x $HTGC Hercules Capital

300 CHF $LISN Lindt & Sprüngli

7 x $MAIN Main Street Capital

1 x $MCD McDonalds

6 x $MDLZ Mondelez

6 x $NOVO B (+0,28 %) Novo Nordisk

5 x $O Realty Income

30 x $OBDC Blue Owl Capital

2 x $PEP PepsiCo

5 x $RIO (+1,92 %) Rio Tinto

10 x $SHEL (-0,09 %) Shell

1 x $V (+1,36 %) Visa

2 x $ZTS Zoetis

The thought here was / is: I like to invest in values that are boring & that I / humanity often see / use / stumble across in my / their daily lives.

I don't buy individual stocks for now, except possibly Zoetis, Main or Salesforce. So far, I have not found any attractive entry points for tech stocks in this portfolio.

One more thing: I don't want to sell everything & shift into the VWRL, and I also know that at 28 I COULD perhaps focus more on growth. The portfolio should be geared towards the long term & dividends motivate me enormously. Just like a beer at the end of the day. 🥸😋

On the side, I still have around CHF 2000 on a crypto exchange $BTC (+1,86 %) Bitcoin lying around.

And now thanks for your opinions. ☺️

I often read FOMO in both directions here at $HIMS

Many are now starting to invest or are partially liquidating their positions, and there are more and more traders who are trying to trade the range of $30 - $70 USD, as this has been successful four times this year.

Why did Hims fall?

Roughly: The elimination of GLP-1 as a direct deal with $NOVO B (+0,28 %) has led to them selling again in a gray area and a lawsuit is always on the table. In addition, compounders have lowered their prices, which has minimized the gap to H&H somewhat. This has meant that Hims has less growth in the GLP-1 area and therefore growth of ~40% is expected for Q3

In addition, ARPU has declined somewhat and Hims has lost momentum in subscriber growth. However, I only see this as a short-term problem as I have adjusted the GLP-1 business and see it as a cash position. In addition, the management is sticking to the 2030 targets which would lead to a FWD P/S of 1.4!!!

The sell-off was also initiated by the sale of shares by the CEO / by the management restructuring and by current market momentum. These factors have led to the current share price decline.

My position has halved since February due to the current price drop, but I am currently considering small purchases (I am an unliquid student) to increase my position a little.

This as a small suggestion, we currently have a P/S of ~3.3!!! I'm off to university now. More to follow

When a billion-dollar company like $NOVO B (+0,28 %) suddenly starts throwing around such cheap advertising, you can see it immediately:

Someone is trying to artificially boost the share price.

$NOVO B (+0,28 %)
$NVO (+0,49 %)

Source: https://vm.tiktok.com/ZNdE3WQgJ/

$NOVO B (+0,28 %) In my view, the bottom has been reached. I re-entered the day before yesterday with 0.5k, buy in 43.18€ (11.580413 shares)

✅ Important resolutions

• The previous Chairman of the Board of Directors, Helge Lund, as well as Vice Chairman Henrik Poulsen and several other previous members of the Supervisory Board resigned.

• The following were newly elected:
• Lars Rebien Sørensen as Chairman of the Supervisory Board.
• Cees de Jong as Vice-Chairman.
• Britt Meelby Jensen and Stephan Engels as new members of the Supervisory Board.

• All new elections are valid until the next Annual General Meeting on March 26, 2026.

Name

Role / Position

Professional & experience background

Lars Rebien Sørensen

Chairman ("Chair")

He was CEO of Novo Nordisk from 2000 to 2016. Later Chairman of the Novo Nordisk Foundation and Novo Holdings.

Cees de Jong

Vice Chairman ("Vice Chair")

Former CEO of Chr. Hansen. According to Reuters, he has many years of management and leadership experience in the life sciences sector.

Britt Meelby Jensen

member

Currently CEO of Ambu, a Danish medical technology company. She also previously worked at Novo Nordisk and has management experience in the biotech industry.

Stephan Engels

member

According to Reuters, former CFO of Danske Bank and previously at Commerzbank. He has experience in finance and banking.

⚠️ Important restrictions:

• Mikael Dolsten was originally on the candidate lists, but has withdrawn his candidacy.

🔍 Strategic analysis of the new Novo Nordisk Board members (EGM 2025)

Novo Nordisk is in an extremely important phase: global expansion, production bottlenecks, political pressure over GLP-1 drugs and massive capital requirements. This is precisely why people have been chosen to fill certain skill gaps on the Executive Board.

1️⃣ Lars Rebien Sørensen - Chairman

🎯 Key competencies

• Longtime Ex-CEO of Novo Nordisk
• Former Chairman of the Novo Nordisk Foundation and Novo Holdings
• Deep knowledge in:
• global pharma strategy
• Regulation & Policy
• R&D management
• Sustainable corporate management

🧠 Why is it important?

He is "Mr. Novo Nordisk".

His election shows: Stability, risk control, long-term vision.

He will be decisive for:

• the expansion of production capacities worldwide
• political influence in the EU & USA
• ensuring sustainable growth (GLP-1 demand is exploding)

2️⃣ Cees de Jong - Vice Chairman

🎯 Key competencies

• Former CEO of Chr. Hansen (Life Sciences & Fermentation)
• Decades of experience in:
• global production
• quality standards
• Biotechnological scaling

🧠 Why is it important?

The biggest challenge for Novo at the moment is manufacturing capacity.

Cees de Jong is a specialist in exactly that.

He brings expertise in:

• efficient production chains
• Scaling microbiological and pharmaceutical processes
• supply chain security

His choice is a clear signalthat Novo Nordisk wants to tackle production problems on a massive scale.

3️⃣ Britt Meelby Jensen - Member

🎯 Key competencies

• CEO of Ambu (MedTech)
• Management experience in the healthcare sector
• Previously worked in the Novo Nordisk Group
• Deep understanding of:
• Medical Technology
• global sales
• operational scaling

🧠 Why is it important?

She brings operational excellence and market understanding from the medical device sector sector.

This is relevant because:

• GLP-1 products are increasingly innovative delivery systems need
• the market for digital health solutions is growing
• Ambu has experience with highly regulated international markets

It strengthens the strategic development of injection systems and patient solutions.

4️⃣ Stephan Engels - Member

🎯 Key competencies

• Former CFO of Danske Bank
• Previously CFO of Commerzbank
• Specialist for:
• Financing of large corporations
• risk management
• major investments
• Capital allocation

🧠 Why is it important?

Novo Nordisk is facing:

• gigantic production investments (billions)
• increasing regulatory and geopolitical risks
• Record sales that need to be reinvested wisely

It is the perfect choice for:

• secure financing for global expansion
• Optimizing balance sheet structures
• Minimizing financial risks

It will be of enormous strategic importance for controlling the GLP-1 boom phase.

🎯

Overall conclusion: Why exactly these four?

✔ Management heavyweight (Sørensen)

→ Strategy, stability, political credibility

Biotechnological production (de Jong)

→ Scaling of GLP-1 production, supply chain security

MedTech & operational excellence (Meelby Jensen)

→ Injection systems, innovation, global product management

✔ Financial strategy & risk control (Engels)

→ Safely managing investments worth billions

This composition is no coincidence.

It precisely addresses Novo Nordisk's greatest challenges:

• production
• global expansion
• regulatory environment
• innovation pressure
• financial and risk structure

The Executive Board 2025 is thus clearly focused on "hyper-growth under control".

┌──────────────────────────────────────────────────────────────┐

│ NOVO NORDISK - MANAGEMENT BOARD (EGM 2025) │

├───────────────────────────────────────┬──────────────────────┤

│ Chairman │ Lars Rebien Sørensen │

│ Expertise: │ Ex-CEO, strategy, │

│ - Global pharma leadership │ Politics, sustain. │

├───────────────────────────────────────┼──────────────────────┤

│ Vice-Chairman │ Cees de Jong │

│ Expertise: │ Production & scaling │

│ - Biotech fermentation │ Supply chain │

├───────────────────────────────────────┼──────────────────────┤

│ Member │ Britt Meelby Jensen │

│ Expertise: │ MedTech, operational │

│ - Injection systems │ Excellence, sales │

├───────────────────────────────────────┼──────────────────────┤

│ Member │ Stephan Engels │

│ Expertise: │ CFO financial expertise │

│ - Financing, risk management │ Capital management │

└──────────────────────────────────────────────────────────────┘

⭐

2. SWOT analysis - New Executive Board 2025

Strengths

• 🧠 Extremely experienced management (Ex-CEO, top manager from the bio & financial world)
• 🔬 Deep expertise in biotechnology & production → Important for GLP-1 scaling
• 💰 Strong financial expertise for the global billion-dollar investments
• 🌍 Global network & political weightespecially through Sørensen
• ⚙️ Operational excellence (Meelby Jensen) for injection systems & devices

Weaknesses

• 👥 Very "classic" managers - innovation culture could suffer from formal structure
• 🧩 Strong focus on production and finance → less on digital health
• ⏳ The challenges are enormous in the short term - learning curve in the new team

Opportunities (chances)

• 📈 Globally growing GLP-1 market (obesity + diabetes)
• 🏭 Expansion of global production sites → Market dominance
• 💡 Expansion of digital health solutions
• 🌐 Political power to shape sustainable pricing rules
• ⚕️ Development of new therapeutic areas

Risks (threats)

• ⚖️ Regulatory pressure (USA, EU)
• 💊 Competition from Lilly (GLP-1 race)
• 🏭 Production bottlenecks can slow down growth
• 🧾 Political pressure on drug prices
• 🤝 Integration of new managers takes time

⭐ 3. individual strategic profiles

1️⃣ Lars Rebien Sørensen - Chairman

💼 Background

• 16 years as CEO of Novo Nordisk
• Leadership of the Novo Nordisk Foundation
• One of the most respected pharmaceutical executives in Europe

🎯 Role on the Board of Directors

• Ensure strategic stability Ensure strategic stability
• Lead political and regulatory relations
• Overall vision and long-term orientation

🧠 Why elected?

He knows Novo "from the inside".

Perfect for a phase in which controlled hyper-growth is necessary.

2️⃣ Cees de Jong - Deputy Chairman

💼 Background

• Ex-CEO of Chr. Hansen
• Production & fermentation specialist

🎯 Role on the Board of Directors

• Expansion and modernization of production capacities
• Global supply chain security
• quality processes

🧠 Why did you choose me?

Because production bottlenecks currently the bottleneck for GLP-1 drugs.

3️⃣ Britt Meelby Jensen - Board Member

💼 Background

• CEO of Ambu (medical technology)
• Experience in the global healthcare sector
• Former Novo manager

🎯 Role on the Board of Directors

• Strengthen innovation pipeline for injection devices
• Patient access & product strategy
• Accelerate operational processes

🧠 Why elected?

Because GLP-1 products support a modern device strategy strategy - disposable pens, new injectors, digital connection.

4️⃣ Stephan Engels - Board Member

💼 Background

• Former CFO of Danske Bank & Commerzbank
• Expert for risk management, financing & large investments

🎯 Role on the Board of Directors

• Financing the global expansion of production
• Optimization of the capital structure
• Protection against regulatory risks

🧠 Why was this chosen?

Novo is facing gigantic investments → he ensures that the financially clean runs smoothly.

⭐ Overall conclusion

The newly elected Management Board is perfectly aligned with the challenges of Novo Nordisk 2025-2030:

• Scaling up production
• Financial security
• Technical innovation in devices
• Strategic stability & policy capability

The selection of individuals is strategically almost ideal for the global GLP-1 boom.

$3350
$NBIS
$CIFR
$NOVO B (+0,28 %)

Since I want to be absolutely transparent here and not always just share the positive purchases, I should also post my sales and gimmicks.

I sold to minimize the risk slightly $3350 to have some capital free and because the $BTC (+1,86 %) could not hold the 100,000 $.

I also have a lot of profits in the loss compensation pot to create clear transparency here too: 8,879.48 .

For the smaller positions in the portfolio such as $NBIS or $CIFR I could also pull the ripcord again at any time if I realize it might go a little lower or the sentiment changes. $IREN (+2,17 %) And $SOFI are my core positions, so nothing will change. Even with $HIMS I see more opportunities to buy and $PATH and $PRCT is holding up very well, I could double again today.

$NOVO B (+0,28 %) and $UNH are more cash positions, I find the valuations super attractive and am convinced that we have a super risk/opportunity potential here, but it can happen that I sacrifice parts of it in favor of tech if I see opportunities or get FOMO. 😊 (possibly also the whole position)

As quickly as it goes up, it can also go down again, be aware of your risk tolerance and don't let your emotions guide you, especially if you are an investor, short-term volatility is irrelevant. $IREN (+2,17 %) can easily jump up again by 20-50% in the event of potential deals.

For anyone who finds this post annoying, just keep scrolling 😁, I just wanted to provide clarity for those people who might buy everything blindly, I think that's the way it should be.

Since I do everything from my cell phone and don't always have time to upload it right away, my purchases / sales don't always come right away and sometimes with a time delay.

And to prove the authenticity of my portfolio for those who question it:

Here are a few explanations 🫡

Yes, fees could be lower, but in Austria as a tax-simple broker and to be able to buy almost any share, hardly any alternatives and I don't want to bother with Trade Republic 😊